A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of MTR-601, a Novel Oral Treatment in Patients With Cervical Dystonia
Latest Information Update: 20 Apr 2025
At a glance
- Drugs MPH-220 (Primary)
- Indications Torticollis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Motric Bio
- 04 Mar 2025 Status changed from not yet recruiting to recruiting.
- 21 Feb 2025 New trial record